The reiteration of an Outperform rating and a maintained price target of $10 by a reputable analyst like David Nierengarten suggests a strong vote of confidence in TScan Therapeutics' potential. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in TCRX's stock price, especially if the market aligns with Wedbush's analysis.